The U.S. Food and Drug Administration (FDA) Generic daily injection approved GLP-1 treatment for type 2 diabetes patients aged 10 years and older.
Currently in short supply, liraglutide injection, sold under the brand name Victoza, will provide a low-cost option for people in need of a GLP-1 treatment.
“Generic drugs provide additional treatment options that are generally more affordable for patients,” Dr. Ayln Murphy, director of the Office of Generic Drugs in the FDA's Center for Drug Evaluation and Research, said in a statement.
According to statistics, more than 38 million Americans, or 1 in 10 people, have diabetes. white house.
“Today's approval confirms FDA's continued commitment to facilitating patient access to safe, effective and high-quality generic drug products,” Murphy added.
Doctors are warning patients with a family history of medullary thyroid cancer or multiple endocrine tumor syndrome type 2 not to take the drug due to possible complications.
According to , some experts said weekly injections showed stronger results than daily injections. CNN coverage.
